The chemical name of molotinib/mometinib

Momelotinib contains momelotinib dihydrochloride monohydrate, a kinase inhibitor with the chemical name n-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide dihydrochloride monohydrate. Molotinib tablets are for oral administration. Each tablet contains 100 mg, 150 mg, or 200 mg of molotinib, equivalent to 121.94 mg respectively. , 182.91mg or 243.88mg of Momelotinib dihydrochloride monohydrate as the active ingredient. Its molecular formula is C23H22N6O2.2HCl.H2O. This structure allows molotinib to effectively bind to its target, thereby exerting anti-tumor effects.

Molotinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anemia who have primary myelofibrosis (MF), post-polycythemia vera (PV) myelofibrosis, or essential thrombocythemia (ET)post-myelofibrosis and are Janus-associated kinase (JAK) inhibitor-naïve or have been treated with ruxolitinib (ruxolitinib). In this setting, molotinib provides an additional treatment option within the therapeutic class of JAK inhibitors.

Molotinib mainly works by inhibitingJAK1 and JAK2 (Janus kinase). The JAK signaling pathway plays a key role in the growth, proliferation and survival of various cells, especially in diseases of the hematological system. By inhibiting these two kinases, molotinib can reduce the proliferation of tumor cells and also help improve patient symptoms, such as anemia and splenomegaly. In some stages of clinical trials, patients had good clinical responses after receiving molotinib treatment, with symptoms significantly improved and hematological indicators returning to normal. This provides new treatment options for patients with myelofibrosis.